Axia Pharmaceutical Recalls Glycine Injection Due to Sterility Concerns
Fusion IV Pharmaceuticals is recalling specific lots of Glycine Injection because the company cannot guarantee the product's sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable medication, which poses a risk of serious infection or adverse health consequences.
Plain-English summary
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical is recalling specific lots of Glycine Injection, GLYCINE USP 50MG/ML INJECTABLE. The recall is being conducted due to a lack of assurance of sterility for the affected products.
The recalled product is a 30 mL multi-dose vial intended for intravenous (IV) and intramuscular (IM) use. It is available by prescription only. The specific lots affected are 07012019+52572 (expiration date 4/6/2020) and 10102019+53106 (expiration date 6/30/2020).
The products were distributed nationwide in the United States, as well as in Puerto Rico, Barbados, and the Dominican Republic. Healthcare providers and patients should check their inventory and discontinue use of the affected lots. The FDA has classified this recall as Class II, indicating that use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Glycine Injection,GLYCINE USP 50MG/ML INJECTABLE, For IV, IM Use,30 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0344-3
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 07012019+52572
- Exp 4/6/2020
- 10102019+53106
- Exp 6/30/2020
Distribution
Part of a larger recall action
This product is one of 63 recalled by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 63 products in this recall →Related recalls
Same manufacturer · Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
See all →- Severe
- SevereAxia Pharmaceutical Recalls Selenium Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- Severe
- SevereAxia Pharmaceutical Recalls Hydroxyprogesterone Caproate Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- SevereAxia Pharmaceutical Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereBeacon Hill Medical Pharmacy Recalls Glycine Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- HighGlycine for injection recalled across all lots over sterility assurance
FDA (Drugs) · 2025-10-15
- SevereFDA Recalls Acetylcysteine Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-05-22
- SevereGreen Valley Drugs Recalls Amikacin Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-22
- SevereGreen Valley Drugs Recalls L-Lysine Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-22
- HighInjectable Glycerin Sterile Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-01